Abstract
Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic disorder with associated monoclonal gammopathy. A wide variety of neuropathies can be associated with WM, but most commonly it is a mild length-dependent sensory neuropathy of unclear etiology. Rituximab is a monoclonal antibody which suppresses mature B-cell populations. It has increasingly been used in wide applications including WM, especially in those cases with severe neuropathy. The highlighted case provides an example of rituximab treatment complication in a WM patient with mild sensory neuropathy that evolved to multiple mononeuropathies with features of systemic vasculitis and unusual conversion of type I to type II cryoglobulinemia.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Murine-Derived
-
Cryoglobulinemia / chemically induced
-
Cryoglobulinemia / immunology
-
Cryoglobulinemia / physiopathology
-
Cyclophosphamide / therapeutic use
-
Disease Progression
-
Female
-
Humans
-
Immunologic Factors / adverse effects*
-
Immunosuppressive Agents / therapeutic use
-
Methylprednisolone / therapeutic use
-
Mononeuropathies / chemically induced*
-
Mononeuropathies / immunology*
-
Mononeuropathies / physiopathology
-
Peripheral Nerves / drug effects*
-
Peripheral Nerves / immunology*
-
Peripheral Nerves / pathology
-
Rituximab
-
Sural Nerve / drug effects
-
Sural Nerve / immunology
-
Sural Nerve / pathology
-
Treatment Outcome
-
Vasculitis / chemically induced
-
Vasculitis / immunology
-
Vasculitis / physiopathology
-
Waldenstrom Macroglobulinemia / drug therapy*
-
Waldenstrom Macroglobulinemia / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Immunologic Factors
-
Immunosuppressive Agents
-
Rituximab
-
Cyclophosphamide
-
Methylprednisolone